LEWISVILLE, Texas--(BUSINESS WIRE)--med fusion, an integrated Molecular Center of Excellence and clinical trials service organization, today announced the release of its Solid Tumor Molecular Profiling testing services (SEQ) enhanced by Next Generation Sequencing (NGS) technology. The introduction of NGS will further enable physicians to interrogate their patient’s tumor at the molecular level in order to develop a personalized treatment plan according to the genetic makeup of their specific tumor.
With integrated and comprehensive testing services, med fusion offers both disease-specific panels (LUNGSEQ, COLONSEQ, COLONSEQPlus) for prioritizing treatment options within Standard of Care guidelines as well as a hot spot cancer panel (50SEQ) by NGS to support treatment options for rare, refractory, or recurrent disease. The SEQ testing results associate therapy options based upon FDA, NCCN, and ASCO guidelines in a complete and tailored report for the patient and physician.
Help employers find you! Check out all the jobs and post your resume.
